Reverses cisplatin resistance in ovarian cancer by inhibiting NF-κB/ECM1 signaling; suppresses the transformation of normal fibroblasts (NFs) into cancer-associated fibroblasts (CAFs), thereby targeting both tumor cells and tumor microenvironment. Here, ECM1 is linked to ovarian carcinoma.